4D Molecular Therapeutics, Inc. SEC filings FDMT
4D Molecular Therapeutics, Inc. has 439 filings in SEC EDGAR's recent list, going back to Aug 13, 2015. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 28, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-3 | Shelf registration | May 7, 2026 | — |
| S-8 | Employee stock plan registration | Mar 18, 2026 | — |
| 424B5 | Prospectus supplement | Nov 6, 2025 | — |
| S-8 | Employee stock plan registration | May 8, 2025 | — |
| POS AM | Filing | Feb 28, 2025 | — |
| S-8 | Employee stock plan registration | Feb 28, 2025 | — |
| 424B5 | Prospectus supplement | Jun 7, 2024 | — |
| S-8 | Employee stock plan registration | Feb 29, 2024 | — |
| 424B5 | Prospectus supplement | Feb 8, 2024 | — |
| FWP | Free writing prospectus | Feb 7, 2024 | — |
| 424B5 | Prospectus supplement | Feb 5, 2024 | — |
| S-3ASR | Automatic shelf registration | Feb 5, 2024 | — |
| S-3 | Shelf registration | Aug 9, 2023 | — |
| 424B5 | Prospectus supplement | May 8, 2023 | — |
| 424B5 | Prospectus supplement | May 4, 2023 | — |
| S-8 POS | Filing | May 4, 2023 | — |
| S-8 | Employee stock plan registration | Mar 15, 2023 | — |
| S-3 | Shelf registration | Aug 23, 2022 | — |
| S-3 | Shelf registration | Mar 29, 2022 | — |
| S-8 | Employee stock plan registration | Mar 28, 2022 | — |
| 424B4 | Prospectus | Nov 1, 2021 | — |
| S-1 | Registration statement | Oct 26, 2021 | — |
| S-8 | Employee stock plan registration | Mar 25, 2021 | — |
| S-8 | Employee stock plan registration | Dec 15, 2020 | — |
| 424B4 | Prospectus | Dec 14, 2020 | — |
| S-1MEF | Filing | Dec 10, 2020 | — |
| S-1/A | Amended registration statement | Dec 10, 2020 | — |
| S-1/A | Amended registration statement | Dec 7, 2020 | — |
| S-1 | Registration statement | Nov 17, 2020 | — |
| S-1 | Registration statement | Sep 30, 2019 | — |
Showing 30 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- FDMT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Emeryville, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1650648
- Former names
- 4D Molecular Therapeutics Inc. (until May 12, 2022); 4D Molecular Therapeutics Inc (until Sep 30, 2019)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.